Logo image of TENX

TENAX THERAPEUTICS INC (TENX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:TENX - US88032L6056 - Common Stock

14.7 USD
+1.4 (+10.53%)
Last: 1/12/2026, 8:00:01 PM
Fundamental Rating

3

Taking everything into account, TENX scores 3 out of 10 in our fundamental rating. TENX was compared to 528 industry peers in the Biotechnology industry. While TENX has a great health rating, there are worries on its profitability. TENX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TENX has reported negative net income.
In the past year TENX has reported a negative cash flow from operations.
TENX had negative earnings in each of the past 5 years.
TENX had a negative operating cash flow in each of the past 5 years.
TENX Yearly Net Income VS EBIT VS OCF VS FCFTENX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

Looking at the Return On Assets, with a value of -42.14%, TENX is in line with its industry, outperforming 57.77% of the companies in the same industry.
The Return On Equity of TENX (-45.03%) is better than 68.94% of its industry peers.
Industry RankSector Rank
ROA -42.14%
ROE -45.03%
ROIC N/A
ROA(3y)-136.22%
ROA(5y)-220.51%
ROE(3y)-284.78%
ROE(5y)-368.86%
ROIC(3y)N/A
ROIC(5y)N/A
TENX Yearly ROA, ROE, ROICTENX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

TENX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TENX Yearly Profit, Operating, Gross MarginsTENX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for TENX has been increased compared to 1 year ago.
The number of shares outstanding for TENX has been increased compared to 5 years ago.
TENX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TENX Yearly Shares OutstandingTENX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
TENX Yearly Total Debt VS Total AssetsTENX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

TENX has an Altman-Z score of 2.36. This is not the best score and indicates that TENX is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of TENX (2.36) is better than 67.05% of its industry peers.
TENX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.36
ROIC/WACCN/A
WACCN/A
TENX Yearly LT Debt VS Equity VS FCFTENX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M 80M

2.3 Liquidity

TENX has a Current Ratio of 15.58. This indicates that TENX is financially healthy and has no problem in meeting its short term obligations.
TENX has a Current ratio of 15.58. This is amongst the best in the industry. TENX outperforms 92.42% of its industry peers.
A Quick Ratio of 15.58 indicates that TENX has no problem at all paying its short term obligations.
TENX's Quick ratio of 15.58 is amongst the best of the industry. TENX outperforms 92.42% of its industry peers.
Industry RankSector Rank
Current Ratio 15.58
Quick Ratio 15.58
TENX Yearly Current Assets VS Current LiabilitesTENX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

TENX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 93.76%, which is quite impressive.
EPS 1Y (TTM)93.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-110.53%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 14.49% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y73.69%
EPS Next 2Y30.36%
EPS Next 3Y20.2%
EPS Next 5Y14.49%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TENX Yearly Revenue VS EstimatesTENX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
TENX Yearly EPS VS EstimatesTENX Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -5K -10K -15K -20K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TENX. In the last year negative earnings were reported.
Also next year TENX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TENX Price Earnings VS Forward Price EarningsTENX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TENX Per share dataTENX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

A more expensive valuation may be justified as TENX's earnings are expected to grow with 20.20% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.36%
EPS Next 3Y20.2%

More info and screens

0

5. Dividend

5.1 Amount

TENX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

TENAX THERAPEUTICS INC

NASDAQ:TENX (1/12/2026, 8:00:01 PM)

14.7

+1.4 (+10.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/amc
Earnings (Next)03-23 2026-03-23/amc
Inst Owners95.19%
Inst Owner Change0%
Ins Owners0.34%
Ins Owner Change0.26%
Market Cap91.73M
Revenue(TTM)N/A
Net Income(TTM)-43.33M
Analysts87.27
Price Target25.76 (75.24%)
Short Float %8.52%
Short Ratio3.91
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-17.89%
Min EPS beat(2)-25.49%
Max EPS beat(2)-10.29%
EPS beat(4)1
Avg EPS beat(4)-4.89%
Min EPS beat(4)-41.99%
Max EPS beat(4)58.23%
EPS beat(8)3
Avg EPS beat(8)-0.88%
EPS beat(12)7
Avg EPS beat(12)11.89%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)12.22%
PT rev (3m)20.24%
EPS NQ rev (1m)-1.22%
EPS NQ rev (3m)-12.93%
EPS NY rev (1m)-0.55%
EPS NY rev (3m)-11.13%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.95
P/tB 0.95
EV/EBITDA N/A
EPS(TTM)-1.13
EYN/A
EPS(NY)-1.6
Fwd EYN/A
FCF(TTM)-4.15
FCFYN/A
OCF(TTM)-4.15
OCFYN/A
SpS0
BVpS15.42
TBVpS15.42
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -42.14%
ROE -45.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-136.22%
ROA(5y)-220.51%
ROE(3y)-284.78%
ROE(5y)-368.86%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.58
Quick Ratio 15.58
Altman-Z 2.36
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)93.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-110.53%
EPS Next Y73.69%
EPS Next 2Y30.36%
EPS Next 3Y20.2%
EPS Next 5Y14.49%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-203.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-36.04%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-268.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-267.96%
OCF growth 3YN/A
OCF growth 5YN/A

TENAX THERAPEUTICS INC / TENX FAQ

What is the ChartMill fundamental rating of TENAX THERAPEUTICS INC (TENX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to TENX.


What is the valuation status of TENAX THERAPEUTICS INC (TENX) stock?

ChartMill assigns a valuation rating of 1 / 10 to TENAX THERAPEUTICS INC (TENX). This can be considered as Overvalued.


What is the profitability of TENX stock?

TENAX THERAPEUTICS INC (TENX) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for TENX stock?

The Earnings per Share (EPS) of TENAX THERAPEUTICS INC (TENX) is expected to grow by 73.69% in the next year.